AR097739A1 - Imidazo[1,2-a]piridina-7-aminas - Google Patents

Imidazo[1,2-a]piridina-7-aminas

Info

Publication number
AR097739A1
AR097739A1 ARP140103520A ARP140103520A AR097739A1 AR 097739 A1 AR097739 A1 AR 097739A1 AR P140103520 A ARP140103520 A AR P140103520A AR P140103520 A ARP140103520 A AR P140103520A AR 097739 A1 AR097739 A1 AR 097739A1
Authority
AR
Argentina
Prior art keywords
aggregates
compounds
lower alkyl
piridina
aminas
Prior art date
Application number
ARP140103520A
Other languages
English (en)
Inventor
Grobbi Luca
Krust Henner
Koerner Matthias
Muri Dieter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR097739A1 publication Critical patent/AR097739A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente se refiere a compuestos de la fórmula general (1) en la que: R¹ es alquilo inferior o alquilo inferior sustituido por halógeno; R², R³ son hidrógeno o tritio; o a una sal de adición de ácido farmacéuticamente aceptable. Los compuestos pueden utilizarse para la unión a y para el análisis por la imagen de agregados tau y agregados afines de tipo hoja b, aparte de otros agregados de b-amiloides o de agregados de a-sinucleína. Los compuestos de la presente pueden utilizarse para el tratamiento de enfermedades del sistema nervioso central (SNC).
ARP140103520A 2013-09-26 2014-09-24 Imidazo[1,2-a]piridina-7-aminas AR097739A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13186074 2013-09-26

Publications (1)

Publication Number Publication Date
AR097739A1 true AR097739A1 (es) 2016-04-13

Family

ID=49230646

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140103520A AR097739A1 (es) 2013-09-26 2014-09-24 Imidazo[1,2-a]piridina-7-aminas

Country Status (12)

Country Link
US (1) US9957266B2 (es)
EP (1) EP3049411B1 (es)
JP (1) JP6182668B2 (es)
KR (1) KR101770532B1 (es)
CN (1) CN105579453B (es)
AR (1) AR097739A1 (es)
CA (1) CA2920068A1 (es)
HK (1) HK1220201A1 (es)
MX (1) MX2016003422A (es)
RU (1) RU2671506C2 (es)
TW (1) TWI518087B (es)
WO (1) WO2015044095A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014177458A1 (en) * 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES
WO2016033440A1 (en) * 2014-08-29 2016-03-03 Chdi Foundation, Inc. Probes for imaging huntingtin protein
MY196981A (en) 2016-07-22 2023-05-16 Ac Immune Sa Compounds for imaging tau protein aggregates
JP7059270B2 (ja) 2016-07-22 2022-04-25 エーシー・イミューン・エス・アー タウタンパク質凝集体を画像化するための化合物
EP3652329B1 (en) * 2017-07-12 2023-10-04 Dana-Farber Cancer Institute, Inc. Compounds for tau protein degradation
WO2019145291A1 (en) 2018-01-24 2019-08-01 Ac Immune Sa Gamma-carboline compounds for the detection of tau aggregates
WO2019145292A1 (en) 2018-01-24 2019-08-01 Ac Immune Sa Azacarboline compounds for the detection of tau aggregates

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA62972C2 (en) * 1997-07-03 2004-01-15 Application of imidazopyrimidins and imidazopyridins for the treatment of neural disorders
GB9927687D0 (en) * 1999-11-23 2000-01-19 Merck Sharp & Dohme Therapeutic agents
ES2395721T3 (es) 2000-08-24 2013-02-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Derivados de tioflavina y su uso en diagnosis y terapia de la enfermedad de alzheimer
EP1381604B1 (en) * 2001-04-23 2006-12-27 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents
WO2003018070A1 (en) 2001-08-27 2003-03-06 The Trustees Of The University Of Pennsylvania Stilbene derivatives and their use for binding and imaging amyloid plaques
CA2438032C (en) * 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
CN1784392A (zh) * 2003-03-14 2006-06-07 匹兹堡大学 苯并噻唑衍生物化合物、组合物及用途
WO2007002540A2 (en) * 2005-06-24 2007-01-04 Kung Hank F Radiolabeled-pegylation of ligands for use as imaging agents
EP1956013B1 (en) 2005-11-30 2016-04-13 Fujifilm RI Pharma Co., Ltd. Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
US7700616B2 (en) * 2006-05-08 2010-04-20 Molecular Neuroimaging, Llc. Compounds and amyloid probes thereof for therapeutic and imaging uses
US20100092385A1 (en) * 2007-01-22 2010-04-15 Astrazeneca Ab Novel Heteroaryl Substituted Imidazo [1,2-A] Pyridine Derivatives
JP5322180B2 (ja) * 2007-07-04 2013-10-23 国立大学法人東北大学 フッ素およびヒドロキシ基で置換されたアルコキシ基を有するｐｅｔプローブ
AU2008319985A1 (en) * 2007-10-30 2009-05-07 Nihon Medi-Physics Co., Ltd. Use of novel compound having affinity for amyloid, and process for production of the same
SI2338059T1 (sl) * 2008-09-23 2015-08-31 Wista Laboratories Ltd. Ligandi za agregirane molekule tau
US8691187B2 (en) * 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
PL2480546T3 (pl) * 2009-09-24 2015-05-29 Hoffmann La Roche Pochodne imidazopirydyny i imidazopirymidyny jako inhibitory fosfodiesterazy 10A
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
WO2014177458A1 (en) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES

Also Published As

Publication number Publication date
MX2016003422A (es) 2016-06-28
KR20160048166A (ko) 2016-05-03
CN105579453B (zh) 2017-12-22
RU2016112547A (ru) 2017-10-31
RU2016112547A3 (es) 2018-05-25
CN105579453A (zh) 2016-05-11
HK1220201A1 (zh) 2017-04-28
US20160207919A1 (en) 2016-07-21
TWI518087B (zh) 2016-01-21
KR101770532B1 (ko) 2017-08-22
US9957266B2 (en) 2018-05-01
TW201516046A (zh) 2015-05-01
JP2016533334A (ja) 2016-10-27
CA2920068A1 (en) 2015-04-02
EP3049411A1 (en) 2016-08-03
WO2015044095A1 (en) 2015-04-02
JP6182668B2 (ja) 2017-08-16
RU2671506C2 (ru) 2018-11-01
EP3049411B1 (en) 2017-04-26

Similar Documents

Publication Publication Date Title
AR097739A1 (es) Imidazo[1,2-a]piridina-7-aminas
CL2017001572A1 (es) Compuestos de triazolopirimidina y usos de los mismos.
CO2019000686A2 (es) Compuestos de indol sustituidos con [1,2,4]triazolo[1,5-a]piridinilo
CR20150663A (es) Derivados de diazacarbazol como ligandos de tau para pet
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
AR095885A1 (es) Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2
AR098912A1 (es) Inhibidores de syk
CR20160523A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
EA201990240A1 (ru) Новые трициклические соединения в качестве противораковых средств
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
CU24603B1 (es) Imidazopirimidinas diazabicíclicas sustituidas útiles en el tratamiento de trastornos respiratorios
AR093759A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR101177A1 (es) Inhibidores de la syk
BR112015009649A2 (pt) composto de triazolo
AR091781A1 (es) Antagonistas del receptor de 5-ht3
AR099047A1 (es) Derivados etinilo
AR095015A1 (es) Compuestos de azetidiniloxifenilpirrolidina
ECSP13012366A (es) Procedimiento de preparación de la sal de l-arginina de perindoprilo
AR101290A1 (es) Inhibidores de aldosterona sintasa
AR099529A1 (es) Derivados de etinilo, un proceso para su fabricación; composiciones farmacéuticas que los comprenden y su uso en el tratamiento de enfermedades del sistema nervioso o cáncer
AR088414A1 (es) Derivados sustituidos de indol
AR099767A1 (es) Derivados del ácido acético azaindol y su uso como moduladores del receptor de prostaglandina d2

Legal Events

Date Code Title Description
FB Suspension of granting procedure